Long-Term Patient-Customized Therapy for a Pathogenic EPO Mutation

Area of Science:

• Genetics
• Hematology
• Molecular Biology

Background:

• Genomic advances identify rare mutations causing severe diseases.
• Novel pathogenic mutation discovered in the erythropoietin (EPO) gene.
• Patient presented with profound hypoplastic anemia due to the EPO gene mutation.

Observation:

• A 5-month-old patient with hypoplastic anemia was treated with recombinant erythropoietin.
• Dosage initiated at 500 units (50 U/kg), then increased to 800 units thrice weekly.
• Blood counts were monitored over a 4-year period.

Findings:

• Prompt response observed with recombinant erythropoietin therapy.
• Hemoglobin levels increased to 12.8 g/dL; red cell count rose to 4.89×10^6/uL.
• Patient achieved transfusion independence and maintained normal hemoglobin without adverse effects.

Implications:

• Patient-customized therapies are effective for rare genetic disorders.
• Existing clinical treatments can be repurposed for novel genetic conditions.
• Successful EPO therapy highlights potential for managing genetic anemias.